comparemela.com
Home
Live Updates
AUTO4 CAR T-Cell Therapy Is Well Tolerated in R/R TRBC1+ Per
AUTO4 CAR T-Cell Therapy Is Well Tolerated in R/R TRBC1+ Per
AUTO4 CAR T-Cell Therapy Is Well Tolerated in R/R TRBC1+ Peripheral T-Cell Lymphoma
The CAR T-cell therapy AUTO4 was not associated with dose-limiting toxicities and led to early indications of efficacy in patients with relapsed/refractory TRBC1-positive peripheral T-cell lymphoma.
Related Keywords
United Kingdom ,
Switzerland ,
Lugano ,
Ticino ,
Janssen Incyte ,
Kate Cwynarski ,
International Conference On Malignant Lymphoma ,
Annual International Conference ,
University College London Hospital ,
International Conference ,
Malignant Lymphoma ,
Internationalt Cell ,
International Conference On Malignant Lymphoma 2023 ,
Hematologic Oncology ,
Conference ,
News ,
Non Hodgkin Lymphoma ,
Nhl ,
Cart Cell Therapy ,